- Home
- AGI vs PODD Comparison
AGI vs PODD Comparison
Compare AGI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGI | PODD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 17.0B |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AGI | PODD |
|---|---|---|
| Price | $52.30 | $243.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 20 |
| Target Price | $44.33 | ★ $358.00 |
| AVG Volume (30 Days) | ★ 4.3M | 1.0M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $55.02 | $24.33 |
| Revenue Next Year | $13.09 | $19.33 |
| P/E Ratio | ★ $34.21 | $69.61 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $22.78 | $230.08 |
| 52 Week High | $55.41 | $354.88 |
Technical Indicators
Market Signals| Indicator | AGI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 41.60 |
| Support Level | $25.15 | $238.68 |
| Resistance Level | N/A | $299.75 |
| Average True Range (ATR) | 2.42 | 9.08 |
| MACD | 0.61 | 1.09 |
| Stochastic Oscillator | 77.35 | 19.72 |
Price Performance
Historical ComparisonAbout AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.